PreClinical Services

SNBL USA is committed to providing clients with quality you expect with your preclinical needs. We are committed to providing service you trust with the turnaround you need.

Nucleic Acid Therapeutics

As a drug class, Nucleic Acid-based Therapeutics represents a diverse spectrum of chemistry, constructs, and delivery options.

Laboratory Services

Blending our strengths, SNBL USA’s laboratory services division represents a powerful resource to extend discovery and development capabilities while still providing superior, individualized service to each client.


SNBL USA Appoints Monica Vegarra as Director of Toxicology Support Services

Posted on Jun 25, 2015

SNBL USA Appoints Monica Vegarra as Director of Toxicology Support Services

Everett, WA – June 25, 2015 – SNBL USA, the experts in preclinical research, today announced Monica Vegarra has joined the executive team to serve in the newly created role of Director of Toxicology Support Services. In this position Monica will assume leadership for the husbandry, specimen management and specimen shipping teams, drive strategic plans, policies, and procedures while ensuring the quality and integrity of the data generated by SNBL USA. “We are fortunate to have Monica on board as this role represents our commitment in strengthening SNBL USA as a leading, innovative...

Read More

Visit SNBL USA at the American Society of Gene & Cell Therapy (ASGCT) 18th Annual Meeting

Posted on May 14, 2015

SNBL USA will be at the American Society of Gene & Cell Therapy (ASGCT) 18th Annual Meeting this week in New Orleans. If you are attending ASGCT, the largest gene and cell therapy conference in the world, stop by booth #124. That is where we will be showcasing the molecular biology and stem cell services we offer to support gene therapy studies. See you in New Orleans! American Society of Gene & Cell Therapy 18th Annual Meeting...

Read More

Urinary Biomarkers for Drug-induced Renal Toxicities in Cynomolgus Monkeys

Posted on May 12, 2015

Pre-SOT Abstract: Blood urea nitrogen (BUN) and creatinine (CRN) have been used as biomarkers (BMs) for detecting drug-induced renal toxicities. Since FDA and EMA proposed several BMs in rats, such as urinary protein, albumin (ALB), β2-microglobulin (B2M), clusterin (CLU) and cystatin C (CysC), we examined the availability of these urinary BMs in cynomolgus monkeys. We used 3 renal toxic compounds: gentamicin (GM), cisplatin (CDDP) and puromycin aminonucleoside (PAN). Three cynomolgus monkeys/group (total 9 animals) received GM (sc, 40 mg/kg/day, 7 days), CDDP (iv, 3 mg/kg, single dose) or...

Read More